Join Nick Brownstone, MD, and Jennifer Bares, MD, as they interview our attendees from the Welcome Reception!

Transport back to the 80s with our dance party!

In this 4-part lecture, Boni E. Elewski, MD, April W. Armstrong, MD, MPH, Erin E. Boh, MD, PhD, and Kristina Callis Duffin, MD, provided the audience with clinical...

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases encountered by dermatologists on a daily basis. In this session, Peter Lio, MD, and April W....

While topical steroids are a mainstay of psoriasis treatment, side effects of long-term use limit their ability to be used on a daily basis. In this session, Alexandra...

In this session, Cheri Frey, MD, provided an in-depth look at popular cosmeceutical ingredients on the market that all dermatologists should be aware of. Beginning with retinoids, Dr...

Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening disease characterized by recurrent flares of widespread skin edema, erythema, and pustulation. Intravenous spesolimab, an anti-interleukin-36 receptor...

Advancements in the detection and treatment of melanoma are occurring at a rapid pace. To help the audience keep track of everything, Darrell S. Rigel, MD, MS, provided...

Interleukin-17 inhibitors have become widely used in dermatology since secukinumab’s approval for psoriasis in 2015. In this session, Joseph F. Merola, MD, MMSc, and Bruce E. Strober, MD,...

Atopic dermatitis (AD) is one of the most commonly encountered skin diseases by dermatologists. John Koo, MD, gave the audience an excellent update on the diagnosis and treatment...

In this highly attended lecture, Mark Lebwohl, MD, gave the audience therapeutic pearls for treating some of dermatology’s toughest diseases. Starting out with generalized pustular psoriasis (GPP), Dr...

Generalized pustular psoriasis (GPP) is a rare, chronic, neutrophilic skin disease characterized by recurring flares of widespread erythema, edema, coalescing pustules, and possible systemic symptoms that can be...

In this session, Gary Goldenberg, MD, took the audience on a whirlwind tour through the latest in treatment updates for common dermatologic conditions. Starting off with acne and...

Janus kinase (JAK) inhibitors are one of the hottest topics in dermatology today. In this session, Raj Chovatiya, MD, PhD, MSCI, reviewed the science behind JAK inhibitor therapy...

Hyperpigmentation has many different etiologies and can be a diagnostic and therapeutic challenge for dermatologists. In this session, Susan C. Taylor, MD, discussed tips for differentiating between the...

With the recent approval of baricitinib and ritlecitinib, alopecia areata (AA) is one of the most talked-about diseases in dermatology today. During this session, Natasha A. Mesinkovska, MD,...

Patients with moderate-to-severe atopic dermatitis (AD) often experience chronic pruritus, poor sleep, and decreased quality of life. Rocatinlimab, a monoclonal antibody that targets OX40, is being investigated for...

This multispeaker session is always an audience favorite; this year, the panel included medical, surgical, as well as practice management tips. Erin Boh, MD, PhD, kicked off the...

To help the audience stay up to date on recent literature publications, Dirk Elston, MD, reviewed interesting articles published in the Journal of the American Academy of Dermatology...

To round out the morning review of dermatology literature, Roger I. Ceilley, MD, delighted the audience with a look back at the past year for SKIN: The Journal...

The approval of multiple novel JAK inhibitors for inflammatory dermatoses such as atopic dermatitis and alopecia areata has left many dermatologists wondering how to deal with the FDA-mandated...

Deucravacitinib, an oral selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who...